UBE2E3

Across TCGA pan-cancer cohorts, UBE2E3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated UBE2E3 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher UBE2E3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated UBE2E3 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, GBM, and LSCC are the cancer types where UBE2E3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.293	0.479	.003	33	view →
GBM	DFS	Tertile	All	0.906	0.484	<.001	18	view →
LSCC	DFS	Quartile	II,III,IV	0.427	0.745	.029	8	view →
LUAD	OS	Median	All	0.581	1.000	.001	7	view →
HNSC	OS	Quartile	III,IV	0.711	0.922	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

UBE2E3–PDAC (OS)

Open the PDAC breakdown →